R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group by Sancho, Juan Manuel et al.
Cancer Medicine. 2021;00:1–13.    | 1wileyonlinelibrary.com/journal/cam4
Received: 28 April 2020 | Revised: 30 November 2020 | Accepted: 24 December 2020
DOI: 10.1002/cam4.3730  
O R I G I N A L  R E S E A R C H
R-COMP versus R-CHOP as first-line therapy for diffuse large 
B-cell lymphoma in patients ≥60 years: Results of a randomized 
phase 2 study from the Spanish GELTAMO group
Juan-Manuel Sancho1  |   Rubén Fernández-Alvarez2 |   Francisco Gual-Capllonch3 |   
Esther González-García2 |   Carlos Grande4 |   Norma Gutiérrez5 |   María-Jesús Peñarrubia6 | 
Ana Batlle-López7 |   Eva González-Barca8  |   José-María Guinea9 |   Eva Gimeno10 |   
Francisco-Javier Peñalver11 |   Miguel Fuertes12 |   Mariana Bastos13  |   José-
Ángel Hernández-Rivas14 |   José-María Moraleda15 |   Olga García1 |   Marc Sorigué1 |   
Alejandro Martin5
1Hematology Department, ICO-IJC-Hospital Germans Trias i Pujol, Badalona, Spain
2Hematology Department, Hospital de Cabueñes, Gijón, Spain
3Cardiology Department of Hospital Germans Trias i Pujol, Badalona, Spain
4Hematology Department, Hospital Doce de Octubre, Madrid, Spain
5Hematology Department, Hospital Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain
6Hematology Department, Hospital Clínico de Valladolid, Valladolid, Spain
7Hematology Department, Hospital Marqués de Valdecilla, Santander, Spain
8Hematology Department, ICO-Hospital Durán i Reynals (Hospitalet de Llobregat, Barcelona, Spain
9Hematology Department, Hospital Universitario de Araba, Vitoria, Spain
10Hematology Department, Hospital del Mar, Barcelona, Spain
11Hematology Department, Hospital Universitario Fundación de Alcorcón, Madrid, Spain
12Hematology Department, Hospital Clínico Lozano Blesa, Zaragoza, Spain
13Hematology Department, Hospital Gregorio Marañón, Madrid, Spain
14Hematology Department, Hospital Universitario Infanta Leonor, Madrid, Spain
15Hematology Department, Hospital Virgen de la Arrixaca, Murcia, Spain
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Correspondence
Dr Juan-Manuel Sancho, Hematology 
Department, ICO-IJC-Hospital Germans 
Trias i Pujol, Universitat Autònoma 






The use of non-pegylated liposomal doxorubicin (Myocet®) in diffuse large B-cell 
lymphoma (DLBCL) has been investigated in retrospective and single-arm prospec-
tive studies. This was a prospective phase 2 trial of DLBCL patients ≥60 years old 
with left ventricular ejection fraction (LVEF) ≥55% randomized to standard R-CHOP 
or investigational R-COMP (with Myocet® instead of conventional doxorubicin). The 
primary end point was to evaluate the differences in subclinical cardiotoxicity, de-
fined as decrease in LVEF to <55% at the end of treatment. Secondary objectives 
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1 |  INTRODUCTION
The combination of the monoclonal anti-CD20 antibody rit-
uximab plus chemotherapy with cyclophosphamide, doxoru-
bicin, vincristine, and prednisone (R-CHOP) still constitutes 
the standard first-line regimen for patients with diffuse large 
B-cell lymphoma (DLBCL).1 However, its use is limited es-
pecially in elderly patients due, among other reasons, to car-
diotoxicity derived from doxorubicin. Doxorubicin-induced 
cardiotoxicity is caused by the binding of the drug and the 
ferric ion, producing the formation of free radicals that pro-
vides lipid peroxidation and progressive myocyte damage.2 
The cumulative dose of doxorubicin appears to be the main 
factor involved in the development of cardiotoxicity, and al-
though a threshold of 500 mg/m2 has been established as a 
risk dose, some studies have described early cardiotoxicity 
with doses of only 200 mg/m2.3,4
In addition to clinical symptoms, determination of the left 
ventricular ejection fraction (LVEF) by echocardiography or 
cardiac scintigraphy (multi-gated acquisition [MUGA]) scan is 
the most frequent parameter employed to evaluate cardiotoxic-
ity, and usually a decrease in LVEF precedes the development 
of congestive heart failure.3 In recent years, the measurement of 
cardiac biomarkers, especially troponin and N-terminal pro-B-
type natriuretic peptide (NT-proBNP), has been proposed as a 
method to detect early cardiotoxicity, and several studies have 
shown a relation between raised levels of cardiac biomarkers 
and left ventricular dysfunction, in particular with a decrease in 
LVEF, and the development of heart failure.4-9
Several strategies have been proposed to decrease cardio-
toxicity provoked by anthracyclines in elderly populations. 
These include the administration of reduced doses or slow 
infusions of doxorubicin, use of cardioprotective agents or 
substitution by other antineoplastic agents or by other less 
cardiotoxic anthacyclines, such as mitoxantrone, epirubicin, 
or liposomal formulations of doxorubicin.10-14 Myocet® is a 
non-pegylated liposomal doxorubicin that demonstrated to 
be less cardiotoxic—with similar antitumoral activity—than 
conventional doxorubicin in a phase 3 trial in patients with 
metastatic breast cancer.2 Due to its pharmacokinetic and 
pharmacodynamics profiles, it has also been associated with 
less myelosuppression and mucositis.14 However, its activity 
in lymphoma patients has mainly been investigated in retro-
spective and single-arm prospective studies.15-20
Taking into account this background, we designed a clin-
ical trial for patients ≥60 years old diagnosed with DLBCL 
or grade 3b follicular lymphoma (FL) with normal cardiac 
function, with the main objective of evaluating the possible 
benefits in terms of cardiac toxicity, of the substitution of 
conventional doxorubicin by non-pegylated liposomal doxo-
rubicin (Myocet®, R-COMP arm) as part of R-CHOP therapy.
2 |  MATERIALS AND METHODS
Prospective randomized phase 2 trial (ClinicalTrials.gov 
Identifier: NCT02012088) of newly diagnosed patients 
≥60  years old with non-localized DLBCL or grade 3b FL 
were efficacy, safety, and variations of troponin and N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and LVEF along follow-up.
Ninety patients were included, 45 in each group. No differences were observed in the percent-
age of patients with LVEF <55% at end of treatment (11% in R-CHOP arm vs. 7% in R-COMP 
arm, p = 0.697) or at 4 months (10% vs. 6%, respectively, p = 0.667) and 12 months (8% vs. 7%, 
respectively, p = 1). However, a higher percentage of R-CHOP compared with R-COMP patients 
showed increased troponin levels in cycle 6 (100% vs. 63%, p = 0.001) and at 1 month after treat-
ment (88% vs. 56%, respectively, p = 0.015). Cardiovascular adverse events were seen in five 
R-CHOP patients (nine episodes, four grade ≥3) and in four R-COMP patients (five episodes, all 
grade 1–2). No significant differences in efficacy were observed.
In conclusion, R-COMP is a feasible immunochemotherapy schedule for DLBCL patients 
≥60 years, with similar efficacy to R-CHOP. However, the use of non-pegylated doxorubicin 
instead of conventional doxorubicin was not associated with less early cardiotoxicity, although 
some reduced cardiac safety signals were observed.
Trial registration: ClinicalTrials.gov Identifier: NCT02012088.
K E Y W O R D S
cardiotoxicity, diffuse large B-cell lymphoma, liposomal doxorubicin, N-terminal pro-B-type 
natriuretic peptide, troponin
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with a baseline LVEF ≥55%. The trial was conducted ac-
cording to Good Clinical Practice Guidelines and the 2008 
revision of the Declaration of Helsinki. All patients provided 
written informed consent before participation in this study.
The requirements for the patients to be included were: age 
≥60 years, newly diagnosed non-localized DLBCL or grade 
3b FL (those with localized lymphoma were included in the 
presence of bulky disease) with at least one measurable lesion, 
Eastern Cooperative Oncology Group (ECOG) performance 
status of 0–2, adequate hematological, renal and hepatic pa-
rameters (unless secondary to lymphoma involvement), and 
a baseline LVEF ≥55%. Patients with localized lymphoma, 
history of transformed lymphoma, central nervous system 
(CNS) involvement, or positivity for hepatitis B or C vi-
ruses or human immunodeficiency virus were excluded, as 
were those with clinically significant cardiovascular disease, 
such as non-controlled arterial hypertension, non-controlled 
ventricular or supraventricular arrhythmias, symptomatic 
ischemic heart disease (class II or higher according to the 
Canadian Cardiovascular Society criteria), past or present 
history of congestive heart failure, LVEF <55%, moderate 
to serious left ventricular hypertrophy, and significant valve 
abnormalities. In addition, patients with no adequate window 
to determine LVEF by echocardiography were also excluded.
Physical examination, standard blood tests, thoracic and 
abdominal computed tomography (CT) scan (and cervical 
if clinically indicated) plus positron emission tomography 
(PET) or combined PET/CT scan, and bone marrow biopsy 
were performed at baseline and at the end of treatment. For 
the cardiac evaluation, an electrocardiogram (ECG) and 
determination of the cardiac biomarkers troponin and NT-
proBNP in serum were performed at baseline, 48–72 h after 
the third and sixth cycles of chemotherapy and at the end 
of treatment (1 month after the last cycle of chemotherapy), 
and in the follow-up visits performed 4 and 12 months later 
in each participant institution according to local procedures. 
The LVEF was measured by echocardiograpy at baseline, at 
the end of treatment (1 month after the last cycle of chemo-
therapy), and 4 and 12 months later. For LVEF determina-
tion, the biplane Simpson's method from the apical acoustic 
window was used,21 and the final result for the LVEF at each 
evaluation point was the mean of three measurements.
2.1 | Treatment
Patients were randomized 1:1 to receive R-CHOP (rituximab 
375  mg/m2 [day 1], cyclophosphamide 750  mg/m2 [day 1], 
doxorubicin 50 mg/m2 [day 1], vincristine 1.4 mg/m2 [day 1, 
capped at a maximum of 2 mg], and prednisone 60 mg/m2 [days 
1–5]) or R-COMP (with the same drugs except for conventional 
doxorubicin being replaced by non-pegylated liposomal doxo-
rubicin, Myocet®, at doses of 50 mg/m2 [day 1]), administered 
in both arms every 21 days for a total of six cycles. If the delay 
in the administration of subsequent cycles was greater than 
2  weeks due to toxicity, the patient was withdrawn from the 
study. Reductions of 25% and 50% in the doses of cyclophos-
phamide and doxorubicin (in R-CHOP arm) or in the doses of 
cyclophosphamide and non-pegylated liposomal doxorubicin 
(in R-COMP arm) were mandatory for patients without hema-
tological recovery (minimum neutrophil count of 1 × 109/L and 
platelet count of 75 × 109/L), after 1 or 2 weeks, respectively, of 
the 21-day period of the previous cycle. In the case of grade 3–4 
neuropathy, discontinuation of vincristine was mandatory, but 
the patients were allowed to continue to participate in the trial 
and receive the remaining drugs of the chemotherapy schedule. 
Primary prophylaxis of febrile neutropenia with granulocyte 
colony-stimulating factor was allowed according to the clinical 
practice. CNS prophylaxis with intrathecal chemotherapy (ac-
cording to clinical practice in the hospital) was recommended 
with each cycle of chemotherapy in the presence of increased 
serum lactate dehydrogenase plus involvement of more than 
one extranodal site, or in patients with a high International 
Prognostic Index (IPI) or in those with involvement of, at least, 
one of the following involved sites: paranasal sinus, Waldeyer's 
ring, epidural space, breast, kidney, or testes. Radiotherapy after 
chemotherapy on residual mass in patients with baseline bulky 
disease was also allowed according to the physician's decision.
2.2 | Primary and secondary end points
The primary end point of the study was to evaluate the differences 
in subclinical cardiotoxicity, defined by a decrease in LVEF to 
<55% at the end of treatment (measured by echocardiography 
at 1  month after therapy), in patients receiving the standard 
R-CHOP regimen compared with those treated with R-COMP. 
Considering a non-superiority hypothesis test for two independ-
ent samples with a statistical power of 80%, a significance level 
of 5% and assuming a proportion of subclinical cardiac toxic-
ity in the reference and experimental groups of approximately 
15%22,23 and 5%,22,23 respectively, with 5% dropouts, 45 patients 
in each treatment arm were necessary to be recruited.
Secondary end points were efficacy in terms of overall 
and complete response rates (ORR and CR) in all randomized 
patients, event-free survival (EFS), progression-free survival 
(PFS), overall survival (OS), and safety. Response to treat-
ment was evaluated according to clinical, laboratory results 
and the evaluation of imaging techniques according to the 
criteria defined by Cheson et al.24 EFS was defined as the 
time from inclusion of the patients in the trial until treatment 
failure, including disease progression, treatment discontinua-
tion, or death by any cause. PFS was defined as the time from 
inclusion into the trial until progression/relapse or death by 
any cause. OS was defined as time from study inclusion to 
death by any cause.
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Safety, with special attention to cardiovascular toxicity, 
was evaluated according to clinical signs and laboratory pa-
rameters, and assessment of adverse events (AE) using ver-
sion 4.0 of the NCI-CTCAE scale for grading toxicity, as 
well as the variations in cardiac biomarkers troponin and NT-
proBNP in both arms throughout the study.
The primary end point analysis was carried out in pa-
tients who received six cycles of treatment and in whom 
post-treatment evaluation of LVEF was performed. Efficacy 
analyses were carried out on an intention-to-treat (ITT) 
population, defined as all randomized patients, and in the 
evaluable population, defined as ITT population excluding 
patients who withdrew the trial without a response evalua-
tion. The safety analysis was carried out in a safety popu-
lation, which included all patients that received at least one 
cycle of chemotherapy.
2.3 | Statistical analysis
Baseline demographic and clinical characteristics were 
described as frequency and percentage for categorical 
variables, and median and range for quantitative variables. 
Comparisons of categorical variables between treatment 
groups were studied using the Chi-square test or Fisher's 
exact test, when necessary, while the median test was used to 
compare continuous variables.
For the primary end point (evaluation of differences in 
subclinical cardiotoxicity), the percentage of patients in 
whom the LVEF decreased to <55% at the end of treatment 
in each treatment group was compared using the Chi-square 
test or Fisher's exact test, when necessary. The median LVEF 
at the end of treatment, as well as at 4 and 12 months later, 
and the median of the differences between baseline and end 
of treatment LVEF measures were compared by the nonpara-
metric median test. Comparison of patients with variations in 
cardiac biomarkers throughout the study was made by Chi-
square test or Fisher's exact test, when necessary.
Regarding efficacy, OR and CR rates were compared 
using the Chi-square test or Fisher's exact test, whereas 
EFS, PFS, and OS curves were plotted by the Kaplan–Meier 
method25 and compared by the log-rank test.26
A descriptive analysis of the reported AE (frequency 







Male, n (%) 17/45 (38%) 24/45 (53%) 0.138 41/90 (46%)
Age (years), median 
(range)
74 (60–84) 74 (60–86) 1 74 (60–86)
Baseline LVEF (%), 
median (range)
63 (55–81.4) 65 (55–87.1) 0.204 64 (55–87.1)
Hypertension, n (%) 26/45 (58%) 17/44 (39%) 0.071 43/89 (48%)
Diabetes, n (%) 7/45 (16%) 8/44 (18%) 0.741 15/89 (17%)
Dyslipemia, n (%) 21/45 (47%) 15/44 (34%) 0.227 36/89 (40%)
ECOG <2, n (%) 37/45 (82%) 38/45 (84%) 0.777 75/90 (83%)
B symptoms, n (%) 20/45 (44%) 19/44 (43%) 0.904 39/89 (44%)
Increased LDH level, 
n (%)
29/45 (64%) 23/45 (51%) 0.2 52/90 (58%)
Extranodal 
involvement, n (%)
26/45 (58%) 26/45 (58%) 1 52/90 (58%)
>1 extranodal site 
involved, n (%)
12/45 (27%) 13/45 (29%) 0.814 25/90 (28%)
BM involvement, n (%) 11/44 (25%) 12/45 (27%) 0.857 23/89 (26%)
Bulky disease, n (%) 11/44 (25%) 12/45 (27%) 0.857 23/89 (26%)
Ann-Arbor stage, n (%)
I–II 9/45 (20%) 10/45 (22%) 0.796 19/90 (21%)
III–IV 36/45 (80%) 35/45 (78%) 71/90 (79%)
IPI, (n %)
0–2 25/44 (57%) 26/44 (59%) 0.829 51/88 (58%)
3–5 19/44 (43%) 18/44 (41%) 37/88 (42%)
Abbreviations: BM, bone marrow; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic 
Index; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; WBC, white blood cells.
T A B L E  1  Baseline characteristics of 
the overall series and divided by treatment 
arm
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treatment groups was made using the Chi-square test or 
Fisher's exact test.
No imputation method was used for missing data. Two-
sided p values <0.05 were considered as statistically signif-
icant. All analyses were performed with SPSS v24 (SPSS 
Inc.).
3 |  RESULTS
From October 2013 to February 2016, a total of 90 patients 
with DLBCL from 15 hospitals belonging to the Spanish 
GELTAMO group were prospectively included. Of these, 45 
were randomized to the R-CHOP arm and 45 to the R-COMP 
arm, without significant differences between the two arms 
regarding baseline characteristics (Table 1). The median age 
of the entire series was 74 years (range 60–86), with ECOG 
<2 in 83%; 79% of patients were in advanced stage and 42% 
had an intermediate to high IPI. The median LVEF at study 
entry was 64% (range 55–87.1), and almost half of patients 
had a previous history of hypertension. Figure 1 shows the 
flow chart of the patients along the study. Thirty-eight out 
of 45 patients (84%) and 42/45 (93%) received six cycles of 
R-CHOP and R-COMP, respectively, (p = 0.130) and were 
included in the analysis of the primary end point.
3.1 | Subclinical cardiotoxicity: LVEF and 
cardiac biomarkers
Regarding the primary end point, no significant differences 
were observed between the R-CHOP and R-COMP arms in 
the number of patients with a LVEF <55% determined at the 
end (1 month) of treatment (11% [n =4/36] in the R-CHOP 
arm vs. 7% [3/42] in the R-COMP arm, p  =  0.697), or at 
4 months (10% [n =3/31] in the R-CHOP arm vs. 6% [2/33] in 
the R-COMP arm, p = 0.667) or at 12 months (8% [n =2/24] 
in the R-CHOP arm vs. 7% [2/28] in the R-COMP arm, p = 1) 
after therapy (Table 2). Furthermore, no differences were ob-
served in an exploratory analysis comparing patients with a 
decrease in LVEF below 50% at the end of treatment or dur-
ing follow-up (data not shown), as well as in the number of 










Withdrawal by AE: 3 (subarachnoid hemorrhage, renal 
failure, atrial fibrilla
on)
Death by AE: 3 (gastrointes
nal hemorrhage, sep
c




Withdrawal by AE: 1 (worsening general condi
on)
Death by AE: 2 (sep






(Reasons for exclusion: 3 due to other
lymphoma subtype, 2 due to localized disease, 
1 due to no adequate window to determine 
LVEF, 2 due to physician criteria) 
6 |   SANCHO et Al.
patients with LVEF drop ≥10% at 1, 4, or 12 months after 
treatment compared to baseline LVEF. Similarly, there were 
also no significant differences between the two groups in the 
median LVEF determined at the end of treatment and at 4 and 
12 months, or in the variations in LVEF determined at differ-
ent times compared to the baseline LVEF (Table 2). Finally, 
no differences were detected in the primary end point (LVEF 
<55% at 1  month of treatment) considering all randomized 
patients (9% [n =4/45] in the R-CHOP arm vs. 7% [3/45] in 
the R-COMP arm, p = 1).
With respect to the cardiac biomarkers troponin and NT-
proBNP, a higher percentage of patients showed increased 
troponin levels (compared to baseline values) measured in 
cycle 6 (24/24 [100%] in the R-CHOP arm vs. 17/27 [63%] 
in the R-COMP arm, p = 0.001) and at 1 month after the 
end of treatment (21/24 [88%] in the R-CHOP arm vs. 
14/25 [56%] in the R-COMP arm, p = 0.015), but not after 
cycles 3 or at 4 and 12 months after treatment (Table 3). 
Regarding NT-proBNP, no differences were observed in 
the percentage of patients with increased levels along the 
treatment period (in cycles 3 and 6) and follow-up (1, 4, 
and 12 months after therapy) compared to the baseline lev-
els (Table 3).
3.2 | Efficacy evaluation
OR and CR were observed in 77 (85.5%) and 56 (62%) out 
of the 90 randomized patients, with no differences between 





LVEF <55% at the end of treatment 
(1 month), number of patients (%)
4/36 (11%) 3/42 (7%) 0.697
LVEF <55% at 4 months of the end of 
treatment, number of patients (%)
3/31 (10%) 2/33 (6%) 0.667
LVEF <55% at 12 months of the end of 
treatment, number of patients (%)
2/24 (8%) 2/28 (7%) 1
Variation (difference) ≥10% in baseline 
LVEF (%) compared with LVEF 
1 month after the end of treatment:
5/36 (14%) 4/42 (10%) 0.725
Variation (difference) ≥10% in baseline 
LVEF (%) compared with LVEF 
4 months after the end of treatment:
4/31 (13%) 4/33 (12%) 1
Variation (difference) ≥10% in baseline 
LEVF (%) compared with LVEF 
12 months after the end of treatment:
3/24 (12%) 2/28 (7%) 0.652
LVEF (%) at the end of treatment 
(1 month), median (range)
61 (41–84.6) 63.9 (49–74) 0.820
LVEF (%) at 4 months of the end of 
treatment, median (range)
61 (41–76) 63.7 (53.3–80) 0.129
LVEF (%) at 12 months of the end of 
treatment, median (range)
60.5 (43.2–84) 65 (52–80) 0.091
Variation (difference) in baseline LVEF (%) compared with LVEF 1 month after the end of 
treatment:
Mean (SD) 1.6 (9.3) 2.3 (7.4) 0.793
Median (range) 2 (−23.6 to 24.7) 2.3 (−16.4 to 24.4)
Variation (difference) in baseline LVEF (%) compared with LVEF 4 months after the end of 
treatment:
Mean (SD) 3.7 (6.9) 1.6 (7.5) 0.841
Median (range) 3 (−13 to 28) 2 (−16.7 to 19.4)
Variation (difference) in baseline LEVF (%) compared with LVEF 12 months after the end of 
treatment:
Mean (SD) 1.3 (8.4) 0.4 (6.8) 0.592
Median (range) 3 (−20.3 to 16) 0.5 (−14 to 13)
Abbreviations: LVEF, left ventricular ejection fraction; SD, standard deviation.
T A B L E  2  Subclinical cardiotoxicity 
(LVEF) in both treatment arms throughout 
the treatment
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[80%] and 28 [62%] patients, respectively; OR and CR in 
the R-COMP arm in 41 [91%] and 28 [62%] patients, re-
spectively). We performed an additional efficacy analysis 
including only the 80 patients evaluable for efficacy; 38 
in the R-CHOP arm (3 were excluded due to AE, 3 due to 
death from AE, and the remaining patient due to withdrawal 
of consent) and 42 in the R-COMP arm (2 were excluded 
due to death from AE and the third patient due to AE). OR 
and CR were observed in 77 (96%) and 56 (70%) out of 80 
evaluable patients, respectively, again without differences 
between the R-CHOP and R-COMP groups (ORR of 95% 
vs. 98%, p = 0.498, and CR rate of 74% vs. 67%, p = 0.494, 
respectively).
With a median follow-up of 42 months (range 2.1–61.2) 
for patients alive at the time of analysis, 15 patients in the 
R-CHOP group had died (6 by lymphoma) and 14 in the 
R-COMP arm (10 by lymphoma).The 2-year EFS and PFS 
probabilities for the entire series were 54% (95% confi-
dence interval [CI] 44%–64%) and 61% (95% CI 51%–71%) 
(Figure 2), respectively, without differences between the two 
groups (2-year EFS of 46% [95% CI 31%–61%] vs. 62% [95% 
CI 48%–76%] for R-CHOP and R-COMP patients, respec-
tively, p = 0.083, and 2-year PFS of 59% [95% CI 44%–74%] 
and 62% [95% CI 48%–76%] for RCHOP and R-COMP 
patients, respectively, p = 0.505) (Figure 3).The 2-year OS 
probability for the entire series was 74% (95% CI 65%–83%) 
(Figure 2), but again without significant differences between 
the two groups (75% [95% CI 62%–88%] for R-CHOP pa-
tients vs. 73% [95% CI 60%–86%] for R-COMP patients, 
p = 0.751) (Figure 3).
3.3 | Safety
The main AEs reported by >5% of the patients are listed in 
Table  4. Overall, the most frequent non-hematologic AEs 
were pain (53% of patients), fatigue (51%), infection (49%), 
peripheral neuropathy (31%), constipation (29%). and py-
rexia (28%), with no differences between both arms. Non-
hematological grade 3–4 toxicity was also similar in both 
groups, being infection the most frequent (five patients 






Increased troponin levels at cycle 3, 
number of patients (%)
13/23 (57%) 12/26 (46%) 0.469
Increased troponin levels at cycle 6, 
number of patients (%)
24/24 (100%) 17/27 (63%) 0.001
Increased troponin levels at end of 
treatment (1 month), number of 
patients (%)
21/24 (88%) 14/25 (56%) 0.015
Increased troponin levels at 4 months 
after treatment, number of patients 
(%)
16/21 (76%) 16/22 (73%) 0.795
Increased troponin levels at 12 months 
after treatment, number of patients 
(%)
10/15 (67%) 10/15 (67%) 1
NT-proBNP
Increased NT-proBNP levels at cycle 3, 
number of patients (%)
25/29 (86%) 32/34 (94%) 0.401
Increased NT-proBNP levels at cycle 6, 
number of patients (%)
27/29 (93%) 23/28 (82%) 0.253
Increased NT-proBNP levels at end 
of treatment (1 month), number of 
patients (%)
14/29 (48%) 14/33 (42%) 0.644
Increased NT-proBNP levels at 
4 months after treatment, number of 
patients (%)
14/25 (56%) 12/27 (44%) 0.405
Increased NT-proBNP levels at 
12 months after treatment, number of 
patients (%)
12/18 (67%) 6/17 (35%) 0.063
Abbreviation: NT-pro-BNP, N-terminal pro B-type natriuretic peptide.
T A B L E  3  Cardiac biomarkers (troponin 
and NT-proBNP) in both treatment arms 
throughout the treatment
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R-COMP group). Regarding grade 3–4 hematological toxic-
ity, neutropenia was observed more frequently in R-CHOP 
patients (49% vs. 29%), but this was not translated into more 
incidence of febrile neutropenia, while thrombocytopenia 
and anemia were identical (Table 4).
Cardiovascular toxicity is described in Table 5. Fourteen 
cardiovascular AEs were observed in nine patients, nine AEs 
in five patients who received R-CHOP, and five AEs in four 
patients treated with R-COMP. Four cardiovascular AEs were 
of grade ≥3 (two cases of atrial fibrillation, one heart failure, 
and one myocardial infarction), all of them in the R-CHOP 
group.
A total of 67 serious adverse events (SAEs) were reported 
in 39 patients (26 in 18 patients from the R-CHOP group 
and 41 in 21 patients from the R-COMP group), including 
16 episodes of febrile neutropenia (6 in R-CHOP and 10 in 
R-COMP), 14 infections (7 in each group), 6 episodes of 
bleeding (2 in R-CHOP and 4 in R-COMP), and 4 episodes of 
pyrexia (all in the R-COMP arm). Cardiovascular SAEs were 
reported in only five patients: supraventricular tachycardia 
(n = 2, R-CHOP group), atrial fibrillation (n = 1, R-COMP 
group), myocardial infarction (n = 1, R-CHOP group), and 
heart failure (n = 1, R-CHOP group).
4 |  DISCUSSION
This study demonstrates that non-pegylated doxorubicin in-
stead of conventional doxorubicin as part of the R-CHOP 
regimen did not decrease the incidence of LVEF drop below 
55% at the end of chemotherapy in patients ≥60 years old di-
agnosed with DLBCL with normal baseline cardiac function. 
Moreover, in this series, R-COMP was a feasible immuno-
chemotherapy schedule for patients ≥60 years of age with de 
novo DLBCL, with similar efficacy to R-CHOP.
The main results of this study are concordant with a sim-
ilar previous phase 3 trial by the Austrian AGMT group23 
that compared R-CHOP and R-COMP in 79 adult patients 
with DLBCL and normal cardiac function. In the cited 
study, a low-rate of cardiotoxicity was described in R-CHOP 
and R-COMP patients. However, while in the present study 
no significant differences were observed in the percentage 
F I G U R E  2  Event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) probabilities for the overall series
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of patients with LVEF <55% at the end of treatment (with 
only 11% and 7% of patients with a LVEF below <55% at 
the end of the study in R-CHOP and R-COMP patients, 
respectively), the Austrian group reported higher measure-
ments of LVEF <50% throughout the study in R-CHOP 
patients compared to the R-COMP group (15.8% vs. 4.6%, 
respectively, p  <  0.001), despite similar baseline LVEF 
values in both groups, a surprisingly finding since that 
younger patients were included in the Austrian (median age 
of 65 years and 38% of patients <60 years) compared to our 
study (median age of 74 years and all patients over 60 years 
old), and age is a well recognized risk factor for cardio-
toxicity. However, as in the present study, no differences 
were observed in LVEF values at the end of treatment in 
the R-CHOP compared to the R-COMP group, suggest-
ing that the substitution of conventional doxorubicin by 
non-pegylated doxorubicin does not seem to protect against 
anthracycline-derived subclinical cardiotoxicity, at least in 
terms of LVEF decrease in DLBCL patients. Similar re-
sults regarding LVEF variations were described previously 
in another phase 2 trial of 75 patients with DLBCL treated 
with 8 cycles of R-COMP20; although LVEF measurements 
decreased at most time points, the differences were not sig-
nificant, with a mean change from baseline to the end of 
treatment of −2.6%, very similar to that found in our study 
(Table  2). In addition, despite the lower number of mea-
surements, the present study also suggests a lack of benefit 
in mid-term subclinical cardiotoxicity, with similar LVEF 
measurements at 4 or at 12 months compared to baseline 
LVEF in the R-CHOP and R-COMP arms.
Cardiac biomarkers have been used as a complementary 
method to detect subclinical cardiac toxicity.5-9 Troponin and 
NT-proBNP are related to early cardiac injury and heart fail-
ure, respectively. In the present study, only troponin levels 
more frequently increased in R-CHOP compared to R-COMP 
patients, although this increase was only detectable in cycle 6 
and 1 month after the completion of treatment, but not at the 
other measurement times. This finding suggests the higher 
early cardiotoxicity in the R-CHOP arm with the cumula-
tive doses of conventional doxorubicin, but the absence of 
F I G U R E  3  Event-free survival (EFS), progression-free survival (PFS), and overall survival (OS) probabilities by treatment group (RCHOP 
and R-COMP groups represented in the continuous and dashed lines, respectively)
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differences in troponin levels at other time points of follow-up 
suggests later improvement. In fact, similar NT-proBNP val-
ues were observed in both arms not only throughout treat-
ment (after 3 and 6 cycles of treatment), but also during 
follow-up (1, 4, and 12 months after therapy), conversely to 
the aforementioned study by Fridrik et al,23 in which higher 
NT-proBNP values were detected in the R-CHOP arm at 
cycle 6 and after treatment.
Overall, the frequency of cardiovascular and cardiac 
events was low in both arms despite the advanced age of the 
patients and long-term follow-up, with a total of 14 events 
(9 in R-CHOP and 5 in R-COMP), 4 of being grade ≥3, all 
of them in the R-CHOP arm. These data are similar to those 
of other published studies.16,17,20,23 In the phase 2 trial con-
ducted by Luminari et al.,20 15 out of 75 patients (21%) treated 
with R-COMP (median age 72 years) presented cardiac AEs 
(grade 3–4 in 3 patients, corresponding to cardiac ischemia, 
atrial fibrillation, and congestive heart failure), whereas in 
the Austrian phase 3 trial,23 a total of 9 cardiac SAEs were 
observed, again without differences between R-COMP (5 
cardiac SAEs) and R-CHOP (4 cardiac SAEs). Other stud-
ies with a lower number of patients treated with R-COMP 
also described a low frequency of cardiac events.16,17 
These results are consistent with the previous large phase 3 
T A B L E  4  Number and percentage of patients with adverse events and toxicity (non-hematologic and hematologic) that occurred in >5% 
patients in the R-CHOP and R-COMP arms
Non-hematologic toxicity
Adverse event/toxicity










Pain 48 (53%) 24 (53%) 24 (53%) 1 1 (2%) 1 (2%)
Fatigue 46 (51%) 22 (49%) 24 (53%) 0.673 0 3 (7%)
Infection 44 (49%) 21 (47%) 23 (51%) 0.673 5 (11%) 7 (16%)
Peripheral neuropathy 28 (31%) 15 (33%) 13 (29%) 0.649 1 (2%) 0
Constipation 26 (29%) 13 (29%) 13 (29%) 1 1 (2%) 0
Pyrexia 25 (28%) 12 (27%) 13 (29%) 0.814 0 4 (9%)
Edema 23 (26%) 14 (31%) 9 (20%) 0.227 0 1 (2%)
Renal failure 21 (23%) 9 (20%) 12 (27%) 0.455 - -
Diarrhea 20 (22%) 10 (22%) 10 (22%) 1 0 1 (2%)
Hepatic toxicity 18 (20%) 6 (13%) 12 (27%) 0.114 1 (2%) 3 (7%)
Nausea/vomiting 17 (19%) 8 (18%) 9 (20%) 0.788 - -
Mucositis 16 (18%) 7 (16%) 9 (20%) 0.581 - -
Hyperglucemia 14 (16%) 8 (18%) 6 (13%) 0.561 0 2 (4%)
Anorexia 13 (14%) 6 (13%) 7 (16%) 0.764 - -
Dyspnea 13 (14%) 4 (9%) 9 (20%) 0.134 0 4 (9%)
Skin rash 13 (14%) 8 (18%) 5 (11%) 0.368 - -
Hemorrhage 11 (12%) 5 (11%) 6 (13%) 0.748 1 (2%) 2 (4%)
Hypotension 7 (8%) 4 (9%) 3 (7%) 1 - -
Dizziness 6 (7%) 2 (4%) 4 (9%) 0.677 - -
Thrombosis 5 (6%) 2 (4%) 3 (7%) 1 1 0
Hematologic toxicity










Neutropenia 46 (51%) 27 (60%) 19 (42%) 0.092 22 (49%) 13 (29%)
Febrile neutropenia 18 (20%) 7 (16%) 11 (24%) 0.292 7 (16%) 11 (24%)
Anemia 36 (40%) 18 (40%) 18 (40%) 1 3 (7%) 3 (7%)
Thrombocytopenia 16 (18%) 8 (18%) 8 (18%) 1 4 (9%) 4 (9%)
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randomized study by a French group27 that compared CHOP 
and R-CHOP (eight cycles in each arm) in patients between 
60 and 80 years old and described 8% of grade 3–4 cardiac 
events in the R-CHOP arm, and with the randomized trial 
RICOVER-60 by a German group,28 in which grade 3–4 car-
diotoxicity was present in 3% of R-CHOP-14 patients (after 
six or eight cycles).
Non-cardiovascular toxicity was also similar in both the 
R-CHOP and R-COMP groups, in contrast to some of the 
findings reported by Fridrik et al.23 In fact, whereas in the 
study by the Austrian group the number of SAEs was higher 
in R-CHOP compared to R-COMP patients (40 vs. 26, 
p = 0.029) due to increased infections, this was not the case 
in our study, with more SAEs being observed in the R-COMP 
group because of febrile neutropenia, bleeding and pyrexia 
episodes, and despite a trend to higher incidence of neutro-
penia in R-CHOP patients. In any case, this trend to higher 
neutropenia in the R-CHOP group observed in the present 
study supports a possible lower hematological toxicity with 
liposomal doxorubicin compared to conventional doxorubi-
cin due to its different pharmacokinetics.14 Moreover, no dif-
ferences were observed in the frequency of mucositis, an AE 
that could decrease with liposomal doxorubicin according to 
other studies.15
As could be expected, efficacy was similar in both arms, 
in accordance with previously published data.16,19,20,23 
The CR rate was identical in both arms, but the ORR was 
higher in R-COMP compared to R-CHOP patients, although 
the differences were not significant. The EFS probability 
showed a trend to being higher in the R-COMP arm, but 
PFS and OS were similar in both arms, and in line with 
other studies.19,20,23
There are some limitations in this study that should be 
mentioned. Primary end point was only assessed in 36/45 
and 42/45 patients treated with R-CHOP and R-COMP, 
respectively, that exceeds the planned 5% rate of drop-
outs and could decrease the ability of the study to detect 
differences in subclinical cardiotoxicity, but in almost all 
cases discontinuations were due to non-cardiac events. 
Moreover, LVEF evaluation was done in each partici-
pant institution, subject to interobserver variability, al-
though all measurements were performed with the same 
method.21 However, in addition to the comparisons of the 
differences in LVEF between the two groups at the end of 
treatment, we also analyzed the variations in LVEF along 
the treatment, supporting the main findings of the study, 
which is also consistent with previous studies.20,23 Global 
longitudinal strain (GLS) performed with echocardiog-
raphy, another tool to detect subclinical cardiotoxicity, 
was not performed routinely. Similarly, troponin and NT-
proBNP biomarker measurements were not centralized, 
and thus, comparisons of cardiac biomarker values along 
the treatment and follow-up were made with respect to 
baseline values in each patient. Nonetheless, the absence 
of significant variations of cardiac biomarkers supports 
the main finding of the study regarding the lack of sig-
nificant LVEF changes in R-CHOP- and R-COMP-treated 
patients. The incidence of cardiotoxicity was quite low in 
the present study, as it has been observed in other contem-
porary studies. However, a benefit of liposomal doxorubi-
cin could be observed in selected patients with high risk of 
cardiotoxicity (excluded in the design of the study), such 
as those with previous anthracycline administration, bor-
derline LVEF (50%–55%) or another type of heart disease 
with preserved LVEF.
In conclusion, this randomized trial confirms that the use 
of liposomal doxorubicin instead of conventional doxorubi-
cin in the R-CHOP regimen in older patients with DLBCL 
and a previously normal LVEF does not compromise the ef-
ficacy of the treatment, but neither does it appear to decrease 
early cardiac toxicity, at least in terms of the primary end 
point. Although we observed some signs of reduced cardiac 
toxicity in the R-COMP group, short-term cardiotoxicity was 
also low in the R-CHOP group. Longer follow-up and addi-
tional studies with a greater number of patients are needed to 
determine whether this drug could have benefits in late-onset 
cardiac toxicity.
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Atrial fibrillation 3a 1
Tachycardia 3 1
Bradycardia/tachycardia 0 1
Heart failure 2b 1
Myocardial infarction 1c 0




aGrade 3 in two cases. 
bGrade 3 in one case. 
cCausing death. 
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